FDA Biosimilar Approval Foreshadows IP Litigation Issues

By Sean Sheridan and Archan Ruparel (September 15, 2021, 4:38 PM EDT) -- In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time.[1]

This approval has raised expectations for the potential of biosimilars to lower the costs of biologic drugs as it is expected to be permitted to be substituted for the reference product at the pharmacy.[2]

Collectively, sales of biologics, including biosimilars, have grown substantially in the past several years.

As of 2018, biologics accounted for 36% of all prescription drug spending in the U.S.[3] As the U.S. biologics marketplace continues to evolve, it will be important for both branded biologic...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!